# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
According to data from Benzinga Pro, during Q4, Recro Pharma's (NASDAQ:REPH) reported sales totaled $22.30 million. Despite...
Recro Pharma (NASDAQ:REPH) reported its Q4 earnings results on Tuesday, March 1, 2022 at 04:00 PM. Here's what investors n...
Recro Pharma (NASDAQ:REPH) reported quarterly losses of $(0.04) per share which beat the analyst consensus estimate of $(0.07) ...
Companies Reporting Before The Bell • Precigen (NASDAQ:PGEN) is expected to report earnings for its fourth quarter.
Gainers Biomerica (NASDAQ:BMRA) stock increased by 10.2% to $4.95 during Wednesday's after-market session. The market valu...
When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors a...
Recro Pharma (NASDAQ:REPH) reported quarterly losses of $(0.07) per share which met the analyst consensus estimate. This is a 2...
Here's a roundup of top developments in the biotech space over the last 24 hours: